ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

@article{Fellay2010ITPAGV,
  title={ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C},
  author={Jacques Fellay and Alexander Thompson and Dongliang Ge and Curtis E. Gumbs and Thomas J. Urban and Kevin V. Shianna and Latasha Little and Ping Qiu and Arthur H. Bertelsen and Mark Watson and Amelia Wall Warner and Andrew J. Muir and Clifford A. Brass and Janice Albrecht and Mark S Sulkowski and John McHutchison and David K. Goldstein},
  journal={Nature},
  year={2010},
  volume={464},
  pages={405-408}
}
Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here… CONTINUE READING
Highly Influential
This paper has highly influenced 27 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 234 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia

  • G Stocco
  • Clin. Pharmacol. Ther
  • 2009
1 Excerpt

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

  • D Ge
  • Nature 461,
  • 2009
1 Excerpt

Peginterferon a-2b or a-2a with ribavirin for treatment of hepatitis C infection

  • McHutchison, G J.
  • N. Engl. J. Med
  • 2009
2 Excerpts

Similar Papers

Loading similar papers…